Wednesday, August 18, 2021 The SC24 randomized phase II/III study comparing stereotactic body radiotherapy(SBRT) versus conventional palliative radiotherapy (CRT) for patients with spinal metastases has been permanently closed following primary publication. Trial Objectives: PRIMARY ENDPOINT: Phase II study: The ability to accrue 54 patients over an 18 month period to a study that randomizes patients with spinal metastases to Stereotactic Body Radiotherapy (SBRT) or Standard Conventional Radiotherapy (CRT) within a Canadian multicentre setting. Phase III study: To assess complete pain response in the treatment area at 3 months post-radiation. SECONDARY ENDPOINTS: (1) Complete pain response in the treatment area at 6 months post-radiation; (2) Radiation site progression-free survival (RSS PFS) at 3 and 6 months; (3) Spinal Instability Neoplastic Score at 3 and 6 months; (4) Overall Surivval; (5) Adverse event profile; (6) Healthe-related Quality of Life; (7) Economic Analysis; (8) Radiotherapy Quality Assurance (RTQA) compliance. TERTIARY ENDPOINTS: (1) Radiomics; (2) Biobanking for future correlative studies TERTIARY ENDPOINT: Biobanking for future correlative Studies. Please visit the SC24 trial page for more information. Primary Publication Sahgal A, Myrehaug SD, Siva S, Masucci GL, Maralani PJ, Brundage M, Butler J, Chow E, Fehlings MG, Foote M, Gabos Z, Greenspoon J, Kerba M, Lee Y, Liu M, Liu SK, Thibault I, Wong RK, Hum M, Ding K, Parulekar WR Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases: an open-label, multicentre, randomised, controlled, phase 2/3 trial :ONLINE, 2021 Lancet Oncology https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00196-0/fulltext.
